The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Abstract:Chronic infection and inflammation contribute to around 25% of cancer cases worldwide. While a direct link between several types of human malignancies and inflammation has now been established, in particular at the gastrointestinal level, the relationship between inflammation and thyroid cancer and the pathophysiology of chronic inflammation that induces papillary thyroid carcinoma (PTC) are still subjects of debate. However, several epidemiological and morphological studies have strongly suggested an increased risk of PTC in patients with Hashimoto's thyroiditis (HT). As in HT, an intense immune infiltrate is associated with certain PTC and might play a critical role in the regulation of carcinogenesis and in carcinoma progression. Proinflammatory molecules, such as cytokines and chemokines, which are produced by immune infiltrate in the tumor microenvironment, contribute to the regulation of key cellular processes for cancer onset and progression, in particular for tumor cell proliferation, apoptosis, autophagy, angiogenesis and metastasis. Molecular studies have identified activation of the RET/PTC rearrangement&ndashinduced MAPK signaling pathway as the driving force in the development of PTC in the context of HT. These genetic alterations may be favored by chronic inflammation. In this regard, the RET oncoprotein and its downstream effectors, such as those implicated in the activation of the MAPK pathway, as well as inflammatory molecules of the tumor microenvironment could be promising molecular targets for new therapeutic strategies for thyroid cancer. This review focuses on the complex link between thyroid cancer and chronic inflammation and highlights the different current hypotheses regarding the role of the immune cell microenvironment in the initiation and progression of PTC.
Keywords: Autoimmune Thyroid Diseases; B-lymphocytes; BRAF mutation; CD8+; Chronic infection; Classical TAM activation (TAM1); Dysregulation; Hashimoto's thyroiditis; Hashimoto's thyroiditis (HT); Inflammation; Inflammation-Induced Carcinoma; Macrophages; Medullary thyroid carcinomas; RET/PTC rearrangement-activation; Somatic mutations; T-CD4+; Therapeutic Potential; Thyroid Gland; Thyroid carcinoma; angiogenesis; angiogenesis and metastasis; anti-inflammatory; apoptosis; autophagy; cancer; carcinogenesis; chemokines; chronic inflammation; cytokines; dendritic cells; gastrointestinal level; genetic alterations; hypothyroidism; immune cell microenvironment; interleukin IL-10; leukocyte adhesion; macrophages (TAM); mast cells; membrane-bound small G-protein RAS; metastasis; mitogenic, angiogenic or motogenic factor; mucosa-associated lymphoid tissue (MALT); multicentric tumors; multinodular goiter; natural killer; neoplastic; neoplastic transformation; neutrophils; pancreatic cancer; papillary thyroid carcinoma (PTC); proinflammatory cytokines; prostaglandin E2; thyroid; tumor cell proliferation; tyrosine kinase membrane; vascular endothelial growth factor (VEGF)
Document Type: Research Article
Affiliations: Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, BP69, 06002 Nice cedex 01, France.
Publication date: October 1, 2010
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.